Skip to main content
SRZN logo

SRZN · Surrozen, Inc.

Track SRZN — free
$28.46 -2.21 (-7.21%) At close · Nov 20
Market Cap
$542.49M
Shares
19.06M
Volume · Nov 20 148.86K Avg daily vol (3M) 531.32K

Price & Indicators

 

Key stats

Close
$28.46
Fri 20 Nov
Open
$29.92
Fri 20 Nov
Average volume, 30 days
343K
shares a session
Short interest
3.2M
17.0% of shares · 8.5 days to cover
Day range
$28.25$30.34
Open $29.92 Close $28.46
52-week closing range
$13.10$34.13
Close $28.46 16.6% under the high
Short volume, last session
53%
Last earnings
Mar 22, 2023
Latest filing
10-Q · Nov 9
Price history
Jan 2021 to Nov 2026

Up next

call held Mar 22, 2023

Latest documents

2026
Nov 18
Registration statement S-3
Selling stockholders may resell 5,741,605 private placement shares

Surrozen registers resale of up to 5,741,605 common shares, 2,456,500 pre-funded warrant shares and 4,099,052 Series E warrant shares, bought in an October 20, 2026 tranche of its private placement for approximately $95.1 million gross. The company receives no resale proceeds, but would receive approximately $47.3 million if all warrants are exercised for cash. Proceeds are intended for development of SZN-8141 and SZN-8143.

Read from the first part of this long document
7 source passages
Up to 5,741,605 shares of common stock; pre-funded warrants to purchase up to 2,456,500 shares of common stock; and Up to 4,099,052 shares of common stock issuable upon exercise of Series E common stock warrants. On October 20, 2026, pursuant to that certain securities purchase agreement, dated March 24, 2025, we issued and sold to the selling stockholders at the closing of a second tranche of our private placement: for aggregate gross proceeds of approximately $95.1 million, before deducting placement agent fees and other expenses payable by us. If all these warrants are exercised for cash, we would receive approximately $47.3 million in connection with such exercises. We intend to use the net proceeds from the private placement for the development of our product candidates SZN-8141 and SZN-8143. Open the document at this passage
Nov 16
Current report 8-K Events of Nov 13
Share offering raises expected $60 million at $31.67 per share

Surrozen, Inc. agreed to sell 1,894,540 common shares at $31.67 per share, generating expected gross proceeds of approximately $60 million before discounts and expenses; closing is expected November 16, 2026.

Entered into a material agreement Read from the first part of this long document
2 source passages
On November 13, 2026, Surrozen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 1,894,540 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $31.67 per share. The gross proceeds from the Offering are expected to be approximately $60 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Offering is expected to close on November 16, 2026, subject to the satisfaction of customary closing conditions. Open the document at this passage
Nov 10
Investor event
8141 trial expands to about 150 patients; 2027 data planned

Surrozen expanded its 8141 diabetic macular edema study to about 150 patients, dosed the first patient in the single dose portion and expects 2027 data. About $220 million is expected to fund operations into 2029.

6 source passages
So the background of Surizen is we actually started as a Wnt Biology-focused company. Yeah, so we're pursuing, as Merck did, diabetic macular edema as the initial indication. So about 150 patients total So we announced yesterday that we dosed the first patient in the SAD portion. We have only disclosed that we'll have data from that portion of the study in 2027. I mean, 50 patients on Vibaismo, 50 patients on each of two dose levels of 8141. We also announced that we had about $29 million in proceeds from an ATM purchases last quarter, so that gives us about $220 million, which will take us into 2029. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
SZN-8141 doses first patient in DUET trial

Surrozen received FDA clearance for SZN-8141 in October 2026 and dosed its first patient in the DUET Phase 1b/2a study. It reported a $207.1 million nine-month net loss, $100.4 million cash, and a cash runway into 2029.

Revenue $0 Net loss $129.72M Diluted EPS -$11.02
Read from the MD&A section
4 source passages
We received FDA clearance of our IND application for SZN-8141 in October 2026 and have dosed our first patient in a Phase 1b/2a study in patients with DME called DUET. During the three and nine months ended September 30, 2026, we had net loss of $129.7 million and $207.1 million, including noncash loss of $113.0 million and $171.4 million on changes in fair value of tranche liability and warrant liabilities during the period, respectively. As of September 30, 2026, we had an accumulated deficit of $734.3 million and cash and cash equivalents of $100.4 million. We anticipate a cash runway into 2029, including funding for completion of the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143. Open the document at this passage
Nov 9
Current report 8-K
First DUET patient dosed as cash runway extends into 2029

Surrozen dosed the first patient in the DUET Phase 1b study and plans to expand Phase 2a enrollment from approximately 60 to 150 patients. Third-quarter net loss was $129.7 million, and anticipated cash runway extends into 2029.

Financial results
4 source passages
Surrozen dosed its first patient in the open-label Phase 1b single-ascending-dose portion of DUET, a Phase 1b/2a clinical study evaluating SZN-8141 in patients with diabetic macular edema (DME). Surrozen plans to expand the randomized, double-masked Phase 2a portion of DUET from approximately 60 to 150 patients. Net Loss: Net loss was $129.7 million, including non-cash loss of $113.0 million on changes in fair value of tranche liability and warrant liabilities, for the quarter ended September 30, 2026, compared to a net loss of $71.6 million for the same period in 2025. The Company anticipates its cash, cash equivalents and marketable securities to provide cash runway into 2029, including funding for completion of the expanded DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$10.53M
Trailing 12 months
Net income (TTM)
−$390.21M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-485.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$100.35M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+37.4%
Year over year · more shares
Price change (1Y)
+107.1%
Trailing year
Short interest
17.0%
Latest settlement · 8.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +6%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 73%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +23%
trailing
YTD return +26%
this year
Relative strength +32%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.97% of shares out · ▲ +3.3% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Poor
Revenue growth −67%
Y/Y
EPS growth −49%
Y/Y
Free cash flow $-30.4M
Quant / Vol
risk profile
Very High
Volatility 136%
annualized · 1-yr
Max drawdown −53%
past year
ATR 8.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+6% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
73% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $27 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.97% of shares out · ▲ +3.3% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $28 · 73% Range high $34
vs 200-day avg +10% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
At-the-market offering net proceeds $29.8M October 2026 —
gross proceeds $0.8M the three months ended September 30, 2026 filing —
March 2025 private placement second tranche gross proceeds $95.1M October 2026 —
net proceeds $26.9M the first quarter of 2026 filing —
Pro forma cash and cash equivalents $220.3M as of September 30, 2026 —
Second tranche of March 2025 PIPE and ATM net proceeds $118.9M October 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SRZN
Surrozen, Inc.
this stock
$542.49M +25.9% -67.4% — 17.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
96
% held
82.3%
Net QoQ
+652.3K sh
Top holder
Column Group LLC
Held Float
View
Held by Funds
Fund positions
70
View
Short & Settlement
Short Interest Rising
Shares short
3.2M
Days to cover
8.5d
Change
+103.7K sh
View
Short Volume
Short vol %
53%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
996
Value
$29.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
52.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$3.5M
Net income (FY)
$-242.0M
EPS diluted
$-32.37
View
Filings
SEC Filings
Latest
S-3
Filed
Nov 18, 2026
This year
22

Surrozen registers resale of up to 5,741,605 common shares, 2,456,500 pre-funded warrant shares and 4,099,052 Series E warrant shares, bought in an October 20, 2026 tranche of its private placement for approximately $95.1 million gross. The company receives no resale proceeds, but would receive approximately $47.3 million if all warrants are exercised for cash. Proceeds are intended for development of SZN-8141 and SZN-8143.

View
Exempt Offerings
Offering
$175.0M
Filed
Apr 8, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Surrozen Announces Pricing of $60…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
SRZN -10.0% +11.7% +23.0% -2.0% +25.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -1.4% +20.9% +32.1% +6.7% +24.8%
Key facts CIK 1824893 CUSIP 86889P208 13F (30d) 97 filings 93 filers Visit website Investor relations